Información de la revista
Vol. 42. Núm. 1.
Páginas 16-19 (enero 2018)
Visitas
1363
Vol. 42. Núm. 1.
Páginas 16-19 (enero 2018)
BRIEFS ORIGINALS
Acceso a texto completo
Use of plasma exchange as therapeutic tool in clinical practice
Utilización del recambio plasmático como herramienta terapéutica en la práctica clínica
Visitas
1363
Isabel Laura Campano-Pérez
Autor para correspondencia
isabel.laura.campano.perez@sergas.es

Author of correspondence Isabel Laura Campano-Pérez, Servicio de Farmacia, Complejo Hospitalario Universitario de Pontevedra, Mourente s/n, 36071 Pontevedra. España
, Rosario Olivera-Fernández, Lara González-Freire, Carlos Crespo-Diz
Servicio de Farmacia, Complejo Hospitalario Universitario de Pontevedra, Pontevedra. Spain
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Tablas (2)
Table 1. Grades of recommendation and category for TPE of the American Society for Apheresis (ASFA)3
Tablas
Table 2. Summary of patient characteristics and outcomes after TPE.
Tablas
Mostrar másMostrar menos
Abstract
Objective

To descrive the use of therapeutic plasma exchange in several pathologies and its adjustment to international reference guides.

Method

Observational, descriptive, retrospective study, of all the patients that received plasmapheresis between January 2014-December 2015. We analized the appropriate indication according to the bibliography consulted, and the therapeutic outcome. Indication, replaced volume of plasma, number of sessions and periodicity were established by the Hematology Service depending on the disease and its clinical course.

Results

10 patients (8 women), between 28-72 years old, received therapeutic plasma exchange. The pathologies treated were neurological (9 patients), Waldenstrom disease (1 patient). The technique used was continuous centrifugation with albumin 5% as replacement fluid.

Conclusions

The therapeutic plasma exchange in reviewed patients agreed to reference guides. There was not a direct relation between the recommendation grade and the response obtained. The reduced number of patients is a limitation to obtain conclusive results.

KEY WORDS:
Blood component removal
Plasma Exchange
Plasmapheresis
Neurological diseases
Hematological diseases
Albumin
Resumen
Objetivo

Describir la utilización del recambio plasmático terapéutico (RPT) en distintas patologías y su ajuste a las guías internacionales de referencia.

Método

Estudio observacional, descriptivo y retrospectivo en pacientes que recibieron plasmaféresis entre enero de 2014 y diciembre de 2015. Se analizó la adecuación de su indicación según la bibliografía consultada, así como la respuesta obtenida. El Servicio de Hematología estableció la indicación, el volumen plasmático a recambiar, el número de sesiones y la periodicidad según la enfermedad de base y su evolución clínica.

Resultados

Diez pacientes (8 mujeres) entre 28 y 72 años de edad, recibieron RPT. Las patologías eran de origen neurológico (9 pacientes), enfermedad de Waldenström (1 paciente). La técnica utilizada fue centrifugación continua con albúmina 5% como líquido de reposición.

Conclusiones

El RPT en los pacientes revisados se ajustó a las guías de referencia. No se observó correlación directa entre el grado de recomendación establecido por dichas guías y la respuesta obtenida. El número reducido de pacientes supone una limitación a la hora de extraer resultados concluyentes.

PALABRAS CLAVE:
Recambio plasmático terapéutico
Intercambio de plasma
Plasmaféresis
Enfermedades neurológicas
Enfermedades hematológicas
Albúmina
Texto completo
Introduction

Therapeutic Plasma Exchange (TPE) is an extracorporeal blood purification technique, which consists in the extraction of a specific volume of plasma that is exchanged for a replacement fluid. The aim of this technique is to remove large-molecular-weight substances, pathogens, or immunocomplexes circulating in the plasma that intervene in the pathological immune response and that are considered responsible for a disease or its clinical manifestations.

Although TPE has been used in more than 80 diseases, such as renal, metabolic, autoimmune, rheumatologic, haematologic, neurologic, digestive, and hepatic disease, there is relatively little experience worldwide with this technique. Because these diseases are uncommon, the use of TPE is supported by case series rather than by controlled studies, thus making it difficult to obtain a solid level of evidence.

Currently, TPE plays an important role mainly in the treatment of autoimmune disease and is a valid option in the case of disease refractory to conventional treatment. However, depending on the indications, great variations in outcomes have been observed in clinical practice. The American Society for Apheresis (ASFA) has published guidelines on the use of TPE. The guidelines establish 4 categories that are constantly reviewed and updated taking into account the data provided by published clinical research1.

The objective of this work was to describe the use of TPE in several pathologies and to determine adherence to accepted international guidelines.

Methods

An observational descriptive retrospective study which included all patients who received TPE from January 2014 to December 2015 in a public tertiary hospital.

The ASFA guidelines were used to verify the appropriateness of the indications for TPE1,2. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system was also used. This system assigns grades of recommendation based on the quality of the published evidence (Table 1)3.

Table 1.

Grades of recommendation and category for TPE of the American Society for Apheresis (ASFA)3

Grades of recommendationCategory
GRADE 1 Strong recommendation  GRADE 2 Weak recommendation  TPE accepted as first-line therapy, either as a standalone treatment or in conjunction with other treatments 
Grade A  High-quality evidence based on randomized clinical trials without limitations  II  TPE accepted as second-line therapy, either as a standalone treatment or in conjunction with other treatments 
Grade B  Moderate-quality evidence based on randomized clinical trials with important limitations  III  The role of TPE is not well established, decision-making should be individualized 
Grade C  Low- or very low-quality evidence based on observational studies or case series  IV  TPE is ineffective and even harmful according to published evidence 

TPE, Therapeutic plasma exchange. Extracted from: Laínez-Andrés JM et al. Recambio plasmático terapéutico: aplicaciones en Neurología. Rev Neurol. 2015;60(3): 120-31

The IANUS® electronic clinical record platform was used to obtain the following variables: age, sex, pathology, number of TPEs received in 1 year, replacement fluid used, duration of treatment, concomitant medication, adverse reactions, and response. All data were anonymised according to the procedure established by Law 41/2002 of November 14, 20024.

TPE was performed in the hospital blood bank using a Spectra Optia Apheresis System® with continuous flow centrifugation through a central catheter. Acid-citrate-dextrose (ACD) was used as the anticoagulant. Oral calcium carbonate was administered before the procedure to prevent hypocalcaemia. The extracted plasma volume (PV) was replaced with 5% albumin5.

The Haematology Service established indications, PV to be replaced, and the number and frequency of sessions in all patients based on the underlying disease and its clinical course.

The Pharmacy Service analysed the use of TPE for different pathologies by evaluating the appropriateness of indications using the criteria established by the ASFA and the available literature.

Results

During the study period, TPE was ordered for 11 patients (8 women and 3 men) between 28 years and 72 years of age (median 46 years). Nine patients had pathologies of neurological origin (81.8% of patients), and 1 patient had Waldenström's macroglobulinemia. However, TPE was not performed in 1 patient with acute hypertriglyceridemia associated with severe pancreatitis (monitored in Intensive Care and Endocrinology and Nutrition Services) due to its successful treatment with standard measures (fluid therapy, insulin, diet).

In the group of 9 patients with neurological indications for different pathologies, TPE was used as first-line treatment in a patient with Guillain-Barré syndrome and as an alternative after the failure of standard treatment in the other 8 patients. In the haematologic patient with Waldenström's macroglobulinemia, TPE was used as a first-line treatment to reduce excess paraproteins prior to initiating specific treatment.

In all patients, a 5% human albumin solution equivalent to 1 to 1.5 PV was used as replacement fluid and adjusted according to patient tolerance. The mean replacement fluid volume was 1.27 PV.

During the study period, only 3 of the 10 treated patients underwent more than 1 TPE procedure. There was a median of 6 sessions per TPE procedure (range 1-12 sessions). The duration of each session ranged from 2 to 3 hours.

Concomitant medications administered during TPE were cyclosporine (1 patient), gentamicin (1 patient), amikacin (4 patients), and vancomycin (2 patients). Antiepileptic agents (phenobarbital, phenytoin, and valproic acid) were administered to 1 patient after TPE. Pharmacokinetic monitoring was used to determine and adjust the plasma levels of these agents5.

In all patients, the haematologist administered prophylactic oral calcium carbonate for hypocalcaemia before TPE and intravenous calcium after TPE as needed.

TPE was well tolerated in 70% of the patients, none of whom experienced adverse reactions. During the first session, 1 patient experienced nausea and vomiting, but subsequently showed improved tolerance to treatment. Two patients experienced central catheter-related infections.

Table 2 shows the characteristics of each patient.

Table 2.

Summary of patient characteristics and outcomes after TPE.

Patients  Age  Sex  Indication  Service  Course  No. TPE in 1 year  ASFA recommendation  Treatment line  Post-TPE outcome 
28  Generalized myasthenia gravis, seronegative, resistant  Neurology  Refractory to immunosuppressants, IVIG, and corticosteroids  Category I, grade 1B  2nd  Partial response Good tolerance 
69  Guillain-Barré syndrome with flaccid tetraparesis and areflexia  Neurology  Poor response to treatment with IVIG and corticosteroids  Category III, grade 2C  2nd  No response Good tolerance 
62  Axonal Guillain-Barré syndrome  Neurology  Poor response to corticosteroids Possible compressive medullary syndrome  Category I, grade 1A  1st  No response Good tolerance 
44  Bilateral retrobulbar optic neuromyelitis  Neurology  Severe anaphylactic reaction to rituximab  Category II, grade 1B  2nd  Good response Good tolerance 
50  Progressive demyelinating polyradiculo-neuropathy  Neurology  Good initial response to corticosteroids Subsequent IVIG treatment with poor response  Category I, grade 1B  2nd  Partial response Good tolerance 
68  Eaton-Lambert syndrome  Neurology  No response to treatment  Category II, grade 2C  2nd  Good response Good tolerance Complications due to catheter infection Death 
40  Refractory inflammatory myopathy  Neurology  Refractory to treatment with azathioprine, MTX, cyclosporine, cyclophosphamide, mycophenolate, rituximab  Category IV, grade 2C  2nd  Good response Nausea and vomiting at start of treatment Good overall tolerance 
43  Hypertriglyceridemia  Endocrinology and Nutrition  Resolved in the ICU with intensive serum therapy, absolute diet, and insulin  Category III, grade 2C  Intention to treat  TPE not performed 
72  Voltage-gated potassium channel antibody-associated encephalitis  Neurology  Anticonvulsants, corticosteroids (no response), IVIG (mild response)  Category III, grade 2C  2nd  Good response Complication due to catheter infection (resolved) 
40  Voltage-gated potassium channel antibody-associated encephalitis  Neurology  IGIV, anticonvulsants, corticosteroids  Category III, grade 2C  2nd  Good temporary response Good tolerance 
46  Waldenstrom's macroglobulinemia  Hematology  Anaemia due to chronic treatment TPE initiated to decrease paraproteins and initiate rituximab  Category I, grade 1C  1st  Good response Good tolerance 

ASFA, American Society for Apheresis; ICU, Intensive Care Unit; IVIG, Intravenous immunoglobulin; MTX, Methotrexate; TPE, Therapeutic plasma exchange.

Discussion

In this case series, the most common pathologies were of neurological origin. However, the most favourable result was obtained in the haematologic patient with Waldenström's macroglobulinemia6–8 (patient K; category I, grade 1C)1 in whom hyperviscosity caused by high IgM-protein levels prevented the initiation of treatment. After a single first-line TPE session, treatment with bortezomib and corticosteroids could be initiated. Clinical and analytical stability was achieved, making it unnecessary to initiate treatment with rituximab as originally planned. Despite the complexity of the patient's condition, TPE improved the result of the pharmacological treatment, thus avoiding the use of more complex and expensive therapeutic measures. The literature reports the use of TPE as a pre-treatment measure to reduce hyperviscosity due to high IgM levels, given that hyperviscosity and IgM levels can be reduced by 60% and by 50%, respectively8.

Of the 2 neurological patients diagnosed with Guillain-Barré syndrome3,9, patient C received TPE as a first-line treatment (category I, grade 1A)1. After failing to respond to initial treatment, patient B received TPE as a second-line treatment (category III, grade 2C)1, with poor outcome. Despite the high grade of recommendation for TPE in patient C, the patient did not respond as expected and had to be referred to the Rehabilitation Service. Patient B did not respond to TPE, and the subsequent course of the disease was torpid.

Despite category III and grade 2C1 for TPE, a very favourable initial response was obtained in the 2 patients (I and J) with voltage-gated potassium channel antibody-associated encephalitis10,11. Patient I was discharged with antiepileptic treatment without subsequent readmission, whereas in patient J, despite the good initial response to TPE, the course of the disease was torpid and further TPE procedures were performed after the study period. The patient died. In line with results reported in the literature11, the patients experienced a subjective temporary improvement that was associated with the TPE procedure.

Myasthenia gravis (category I, grade 1B)1 is a neurological indication for which TPE has been shown to be very effective. Patient A had generalized myasthenia gravis, seronegative, and refractory to treatment with immunosuppressants, intravenous immunoglobulins (IVIG), and steroids. TPE led to a partial improvement of symptoms. These results coincide with those of the published literature. A retrospective study by Kumar et al.12 in 35 patients with myasthenia gravis showed short-term improvements in myasthenic seizures. Mandawat et al.13 compared TPE and IVIG for the treatment of myasthenia gravis, and found that both treatments had clinically similar outcomes,

although they recommended IVIG for elderly patients with or without comorbidities and for all other patients with comorbidities. Trantafyllou et al.14 suggested that periodic TPE is safe and effective in controlling the symptoms of patients with moderate to severe myasthenia gravis nonresponsive to immunosuppressive therapy.

TPE was performed in patient G (40 years, with refractory inflammatory myopathy)3,5 who had been previously treated with azathioprine, methotrexate, cyclosporine, cyclophosphamide, mycophenolate, and rituximab without response. Although this disease is an indication (category IV, grade 2C)1 for TPE, this patient benefited from the procedure, with very positive results that led to hospital discharge with prednisone as the only treatment.

Patients D, E, and F had optic neuromyelitis, polyneuropathy, and Eaton-Lambert syndrome3, respectively. They had a good initial response to TPE, although the final outcomes differed between patients (see Table 2).

Adverse reactions to TPE were observed in only 30% of the patients, which is within the range described in the literature (25%-60%)5.

Since TPE may decrease the plasma levels of some drugs5, their pharmacokinetics should be monitored to ensure the efficacy of concomitant treatment.

In conclusion, 80% of the treated patients experienced improvements.

Although the ASFA guidelines were used to verify the appropriateness of the indications for TPE, no direct correlation was observed between the grade of recommendation and the response obtained. This study and its conclusions may be limited by the small sample size.

Funding

No funding declared.

Conflict of interests

None declared.

Contribution to scientific literature

This study provides information on the use of therapeutic plasma exchange in the treatment of selected pathologies in a tertiary care hospital. The relevance of this information lies in the variability found in the literature on indications, guidelines, results obtained, and interactions with standard treatment.

Therapeutic Plasma Exchange is used in the treatment of several autoimmune diseases. These diseases have a low incidence. Information on this procedure will enhance the provision of more comprehensive pharmaceutical care in Hospital Pharmacy Services and contribute to obtaining the best possible therapeutic outcomes.

References
[1]
Schwartz J , Winters JL , Padmanabhan A , Balogun RA , Delaney M , Linenberger ML , et al.
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue.
[2]
Anaya F .
[3]
Laínez-Andrés JM , Gascón-Giménez F , Coret-Ferrer F , Casanova-Estruch B , Santon-ja JM .
Recambio plasmático terapéutico: aplicaciones en Neurología.
[4]
Ley 41/2002, de 14 de noviembre, básica reguladora de la autonomía del paciente y de derechos y obligaciones en materia de información y documentación clínica. Boletín Oficial del Estado, n° 274, (15 de noviembre de 2002).
[5]
Pons-Estel GJ , Serrano R , Lozano M , Cid J , Cervera R , Espinosa G .
Recambio plasmático en las enfermedades autoinmunes sistémicas.
[6]
Treon S .
Proteasome inhibitors in Waldenstron macroglobulinemia.
[7]
Ghobrial IM .
Choice of therapy for patients with Waldenstrom macroglobulinemia.
[8]
Siami GA , Siami FS .
Plasmapheresis and paraproteinemia: cryoprotein-induced diseases, monoclonal gammopathy, Waldenstrom's macroglobulinemia, hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis.
[9]
Gwathmey K , Balogun RA , Burns T .
Neurologic indications for therapeutic plasma Exchange: 2013 update.
[10]
Montojo MT , Petit-Pedrol M , Graus F , Dalmau J .
Espectro clínico y valor diagnóstico de los anticuerpos contra el complejo proteico asociado a canales de potasio.
[11]
Martin IW , Martin CL , Dunbar NM , Lee SL , Szczepiorkowski ZM .
Therapeutic Plasma Exchange as a Steroid-Sparing Therapy in a Patient with Limbic Encephalitis Due to Antibodies to Voltage-Gated Potassium Channels. J. Clin.
[12]
Rajesh K , Birinder SP , Gupta S , Singh G , Kaur A .
Therapeutic plasma exchange in the treatment of myasthenia gravis.
[13]
Mandawat A , Kaminski HJ , Gatter G , Katirji B , Alshekhlee A .
Comparative analysis of Therapeutic options used for Myasthenia Gravis.
[14]
Triantafyllou NI , Grapsa EI , Karanzou E , Psimenou E , Lagguranis A , Dimopoulos A .
Periodic therapeutic plasma exchange in patients with moderate to severe chronic myasthenia gravis non-responsive to immunosuppressive agents: an eight year followup.
Copyright © 2018. Sociedad Española de Farmacia Hospitalaria
Descargar PDF
Idiomas
Farmacia Hospitalaria
Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.